NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $72.64 +2.49 (+3.55%) As of 11:43 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CG Oncology Stock (NASDAQ:CGON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CG Oncology alerts:Sign Up Key Stats Today's Range$68.13▼$71.7550-Day Range$59.85▼$78.2552-Week Range$37.01▼$80.97Volume427,672 shsAverage Volume1.09 million shsMarket Capitalization$6.49 billionP/E RatioN/ADividend YieldN/APrice Target$88.11Consensus RatingModerate Buy Company Overview CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response. CG Oncology has no approved commercial products. Its clinical development program includes studies of cretostimogene alone and in combination with other cancer treatments. The company is led by President and Chief Executive Officer Arthur Kuan.AI Generated. May Contain Errors. Read More CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreCGON MarketRank™: 1.77541928721 of 5 starsCG Oncology scored higher than 36% of companies evaluated by MarketBeat, and ranked 682nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCG Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCG Oncology has a consensus price target of $88.11, representing about 21.3% upside from its current price of $72.64.Amount of Analyst CoverageCG Oncology has only been the subject of 3 research reports in the past 90 days.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($3.00) to ($3.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CG Oncology is -26.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CG Oncology is -26.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCG Oncology has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.92% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 10.96, which indicates bearish sentiment.Change versus previous monthShort interest in CG Oncology has recently increased by 3.86%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.54 News SentimentCG Oncology has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 25 news articles for CG Oncology this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $209,580.00 in company stock.Percentage Held by Insiders4.80% of the stock of CG Oncology is held by insiders.Percentage Held by Institutions26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGON Stock News HeadlinesCG Oncology FY2026 Earnings Forecast Lifted by HC WainwrightNovember 12 at 2:15 AM | americanbankingnews.comCG Oncology (NASDAQ:CGON) Stock Price Target Cut by GuggenheimNovember 11 at 2:51 AM | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 13 at 1:00 AM | Porter & Company (Ad)What CG Oncology (CGON)'s Third Quarter Earnings Means For ShareholdersNovember 10 at 3:37 PM | finance.yahoo.comCG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMCG Oncology Gains on Q3 ResultsNovember 6, 2026 | baystreet.caEarnings Flash (CGON) CG Oncology, Inc. Reports Q3 Revenue $1.6MNovember 6, 2026 | marketscreener.comMCG Oncology (NASDAQ:CGON) Director Sells 1,000 Shares of Company StockOctober 20, 2026 | insidertrades.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $41.52 at the beginning of the year. Since then, CGON stock has increased by 75.0% and is now trading at $72.64. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) released its quarterly earnings data on Friday, November, 6th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. The company earned $1.60 million during the quarter, compared to analysts' expectations of $548 thousand. CG Oncology had a negative net margin of 3,851.09% and a negative trailing twelve-month return on equity of 24.58%. When did CG Oncology IPO? CG Oncology (CGON) raised $340 million in an initial public offering on Thursday, January 25th 2024. The company issued 20,000,000 shares at a price of $16.00-$18.00 per share. Who are CG Oncology's major shareholders? CG Oncology's top institutional shareholders include State Street Corp (3.62%), Jefferies Financial Group Inc. (0.94%), Fisher Asset Management LLC (0.54%) and Candriam S.C.A. (0.42%). Insiders that own company stock include Hong Fang Song, Brian Guan-Chyun Liu, Decheng Capital Global Life Sc, James Mulay, Corleen M Roche and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Micron Technology (MU), NVIDIA (NVDA), SoundHound AI (SOUN), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Broadcom (AVGO) and Definium Therapeutics (DFTX). Company Calendar Last Earnings11/06/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CGON's financial health is in the Green zone, according to TradeSmith. CGON has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CIK1991792 Webcgoncology.com Phone(949) 409-3700FaxN/AEmployees142Year Founded2010Price Target and Rating Average Price Target for CG Oncology$88.11 High Price Target$100.00 Low Price Target$79.00 Potential Upside/Downside+21.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.99 million Net Margins-3,851.09% Pretax Margin-3,851.09% Return on Equity-24.58% Return on Assets-23.40% Debt Debt-to-Equity RatioN/A Current Ratio21.70 Quick Ratio22.20 Sales & Book Value Annual Sales$4.04 million Price / Sales1,605.99 Cash FlowN/A Price / Cash FlowN/A Book Value$11.10 per share Price / Book6.54Miscellaneous Outstanding Shares89,320,000Free Float85,032,000Market Cap$6.49 billion OptionableOptionable Beta0.35 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CGON) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
